John M. Rimoldi
University of Mississippi
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by John M. Rimoldi.
Journal of The American Society of Nephrology | 2005
Trinity Vera; Jeffery R. Henegar; Heather A. Drummond; John M. Rimoldi; David E. Stec
Heme oxygenase (HO) induction has been demonstrated to be beneficial in limiting the extent of cellular damage after ischemia-induced acute renal failure (ARF). Because increased HO activity is associated with the production of carbon monoxide (CO) as well as the potent antioxidant bilirubin, it is unclear which of the two is of greater importance in the protective effects of HO induction. The purpose of this study was to determine the protective role of CO alone in ischemia-induced ARF. Bilateral clamping of the renal pedicle for 40 min was associated with a ninefold increase in the levels of plasma creatinine 24 h after reperfusion as compared with normal plasma creatinine levels; however, administration of CO donor compounds tricarbonyldichlororuthenium(II) dimer, ([Ru(CO)(3)Cl(2)](2), 10 mg/kg) or tricarbonylchloro(glycinato)ruthenium(II) ([Ru(CO)(3)Cl(glycinate)], (CORM-3) 1 h before the onset of ischemia significantly decreased the levels of plasma creatinine 24 h after reperfusion as compared with vehicle-treated mice. Surprising, treatment with the CO donors was associated with an increase in HO activity 24 h after ischemia. For determining whether the protective effects of the CO donors were due to CO or HO-1 induction, experiments were performed in which HO was inhibited before administration of the CO donors. Pretreatment with the HO inhibitor had no effect on the level of plasma creatinine 24 h after reperfusion after treatment with the CO donor compounds. These results suggest that CO itself may be protective and limit renal damage in ischemia induced ARF.
European Journal of Medicinal Chemistry | 2010
Shiby Paul; Cassia S. Mizuno; Hong Jin Lee; Xi Zheng; Sarah Chajkowisk; John M. Rimoldi; Allan H. Conney; Nanjoo Suh; Agnes M. Rimando
Based on the potential of resveratrol as a colon cancer chemopreventive agent, a set of 26 stilbenes were synthesized and tested against the colon cancer cell lines HT-29 and Caco-2. (Z)-4-(3,5-Dimethoxystyryl)aniline (4), (Z)-methyl-4-(3,5-dimethoxystyryl)benzoate (6), and (Z)-1,3-dimethoxy-5-(4-methoxystyryl)benzene (10) showed strong inhibitory activity in vitro. In vivo studies using HT-29 xenografts in immunodeficient mice were conducted with 4, 6 and 10, together with their corresponding trans isomers (3, 5, and 9, respectively), at the dose of 10 mg/kg body weight. Tumor volume was significantly lowered in 3-, 4-, and 9-treated groups. The cis- and trans-amino analogs (4 and 3, respectively) had similar effect on tumor growth, a 40% decrease compared to the control. Analysis of the serum revealed that 4 isomerized to 3, which may explain their similar effects in SCID mice. Stilbenes 5, 6, 9, and 10 retained their configurations in the serum. Stilbenes 6 and 10 lacked tumor-suppressive effect in SCID mice; the serum levels of these analogs were low (18.8 and 15.5 ng/mL, respectively). Stilbene 9, while weakly active in vitro demonstrated good activity in vivo, was found at higher levels in the serum (69.9 ng/mL) compared to 10. The anti-tumorigenic activity of these stilbene analogs may be partly linked to their effects on proteins involved in cell proliferation, as observed by lowered expression of proliferating cell nuclear antigen and upregulation of the cyclin-dependent kinase inhibitor, p27, in the tumor tissues. Overall, identification of the anti-tumorigenic potential of these compounds provides opportunities for their use against colorectal cancer.
Free Radical Biology and Medicine | 2008
Miguel Zabalgoitia; James T. Colston; Seenu V. Reddy; Jeffrey W. Holt; Raymond F. Regan; David E. Stec; John M. Rimoldi; Anthony J. Valente; Bysani Chandrasekar
The objective of this study was to determine whether heme oxygenase-1 (HO-1) or heme metabolites exert cytoprotective effects on interleukin-18-mediated endothelial cell (EC) death. Treatment with interleukin (IL)-18 increased NF-kappaB activation and PTEN induction, suppressed Akt activation, and stimulated EC death. While ectopic expression of p65 enhanced PTEN transcription, adenoviral transduction of dnIkappaB-alpha, dnp65, or dnIKKbeta was inhibitory. Furthermore, IL-18 suppressed HO-1 mRNA expression via enhanced mRNA degradation. Overexpression of HO-1, treatment with HO-1 inducer hemin, or the CO donor cobalt (III) protoporphyrin IX all reversed IL-18-mediated NF-kappaB activation, PTEN induction, Akt suppression, and EC death. Furthermore, hemin induced HO-1 expression, and HO-1 knockdown, HO-1 inhibition, or CO scavengers all reversed the prosurvival effects of hemin. In addition, the CO donors CORM-1 and CORM-3 and the heme metabolites biliverdin and bilirubin attenuated IL-18-induced EC death via a similar signaling pathway. IL-18 induced p38alpha MAPK activation, and suppressed p38beta isoform expression. While p38alpha knockdown attenuated, p38beta knockdown potentiated IL-18-mediated EC death. Hemin and HO-1 reversed IL-18-mediated p38alpha induction and restored p38beta levels. These results demonstrate that IL-18 suppresses HO-1 expression and induces EC death. HO-1 overexpression, HO-1 induction, or treatment with heme metabolites all reverse IL-18-mediated p38alpha MAPK and NF-kappaB activation, PTEN induction, Akt suppression, and EC death. Thus, HO-1 inducers and CO donors may have the therapeutic potential to effectively block IL-18 signaling and reduce IL-18-dependent vascular injury and inflammation.
Tetrahedron | 2000
D. Chuck Dunbar; John M. Rimoldi; Alice M. Clark; Michelle Kelly; Mark T. Hamann
Abstract Antifungal imidazole alkaloids were isolated from the Egyptian Red Sea sponge Leucetta cf chagosensis using HPLC. These compounds were the previously reported naamidine A, B, D and G and the unreported symmetric imidazole alkaloid naamine D. Naamine D possesses moderate antifungal and nitric oxide synthase inhibitory activity. The structure of naamine D was determined using 1D and 2D NMR experiments including 1H–15N HMBC and high resolution mass spectrometry.
Pharmaceutical Research | 2009
Soumyajit Majumdar; Tushar Hingorani; Ramesh Srirangam; Rama Sarma Venkata Subbarahmanya Gadepalli; John M. Rimoldi; Michael A. Repka
PurposeThe aim of this study was to evaluate the contribution of amino acid transporters in the transcorneal permeation of the aspartate (Asp) ester acyclovir (ACV) prodrug.MethodsPhysicochemical characterization, solubility and stability of acyclovir l-aspartate (l-Asp-ACV) and acyclovir d-aspartate (d-Asp-ACV) were studied. Transcorneal permeability was evaluated across excised rabbit cornea.ResultsSolubility of l-Asp-ACV and d-Asp-ACV were about twofold higher than that of ACV. The prodrugs demonstrated greater stability under acidic conditions. Calculated pKa and logP values for both prodrugs were identical. Transcorneal permeability of l-Asp-ACV
Toxicology and Applied Pharmacology | 2009
Ramon Lavado; John M. Rimoldi; Daniel Schlenk
American Journal of Hypertension | 2008
David E. Stec; Trinity Vera; Gerald R. McLemore; Silvia Kelsen; John M. Rimoldi; Rama Sarma V. S. Gadepalli; Michael J. Ryan
\left( {{\text{12}}{\text{.1}} \pm {\text{1}}{\text{.48}} \times {\text{10}}^{ - {\text{6}}} {{{\text{cm}}} \mathord{\left/ {\vphantom {{{\text{cm}}} {\text{s}}}} \right. \kern-\nulldelimiterspace} {\text{s}}}} \right)
Marine Environmental Research | 1998
Daniel Schlenk; David M. Stresser; John M. Rimoldi; L. Arcand; J. McCants; Alison C. Nimrod; W.H. Bensorr
American Journal of Physiology-renal Physiology | 2008
Silvia Kelsen; Bijal J. Patel; Lawson B. Parker; Trinity Vera; John M. Rimoldi; Rama Sarma V. S. Gadepalli; Heather A. Drummond; David E. Stec
was fourfold higher than d-Asp-ACV
Journal of Natural Products | 2009
Haidy Nasr Kamel; Young B. Kim; John M. Rimoldi; Frank R. Fronczek; Daneel Ferreira; Marc Slattery